Response to the comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies"

Pharmacol Res. 2021 Oct:172:105863. doi: 10.1016/j.phrs.2021.105863. Epub 2021 Aug 30.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Cardiovascular System* / drug effects
  • Glucagon-Like Peptide-1 Receptor
  • Humans
  • Retrospective Studies
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

  • Glucagon-Like Peptide-1 Receptor
  • Sodium-Glucose Transporter 2 Inhibitors